Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Current Deferred Revenue: 2012-2019

Historic Current Deferred Revenue for Agios Pharmaceuticals (AGIO) over the last 8 years, with Dec 2019 value amounting to $61.5 million.

  • Agios Pharmaceuticals' Current Deferred Revenue was N/A to $2.5 million in Q1 2022 from the same period last year, while for Mar 2022 it was $2.5 million, marking a year-over-year change of. This contributed to the annual value of $61.5 million for FY2019, which is 33.51% down from last year.
  • Agios Pharmaceuticals' Current Deferred Revenue amounted to $61.5 million in FY2019, which was down 33.51% from $92.5 million recorded in FY2018.
  • In the past 5 years, Agios Pharmaceuticals' Current Deferred Revenue registered a high of $92.5 million during FY2018, and its lowest value of $19.7 million during FY2015.
  • For the 3-year period, Agios Pharmaceuticals' Current Deferred Revenue averaged around $64.0 million, with its median value being $61.5 million (2019).
  • Per our database at Business Quant, Agios Pharmaceuticals' Current Deferred Revenue slumped by 44.89% in 2015 and then surged by 144.49% in 2018.
  • Yearly analysis of 5 years shows Agios Pharmaceuticals' Current Deferred Revenue stood at $19.7 million in 2015, then spiked by 82.62% to $35.9 million in 2016, then increased by 5.37% to $37.8 million in 2017, then surged by 144.49% to $92.5 million in 2018, then slumped by 33.51% to $61.5 million in 2019.